Population Health Management -Increase Lung Cancer Screening in Community Health Centers (LungSMART)
LungSMART
Population Health Management Approaches to Increase Lung Cancer Screening in Community Health Centers - LungSMART UH3 Clinical Trial
2 other identifiers
interventional
18,894
1 country
1
Brief Summary
The long-term goal of LungSMART Utah is to increase the reach of Low-Dose Computed Tomography (LDCT) screening for lung cancer (hereafter referred to as Lung Cancer Screening or LCS) at scale in low-resource healthcare settings.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable lung-cancer
Started Aug 2026
Typical duration for not_applicable lung-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 13, 2026
CompletedFirst Posted
Study publicly available on registry
May 20, 2026
CompletedStudy Start
First participant enrolled
August 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2030
Study Completion
Last participant's last visit for all outcomes
April 1, 2030
May 20, 2026
May 1, 2026
3.7 years
May 13, 2026
May 13, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Stage 1: Completion of eligibility assessment
To evaluate patient-level interventions with respect to increasing completed assessments in Stage 1. The outcome measure will report the proportion of participants who complete the LCS eligibility assessment.
up to 18 weeks
Stage 2: Completion of LCS
To evaluate patient-level interventions with respect to increasing completed LCS in Stage 2. The outcome measure will report the proportion of participants who complete LCS.
up to 30 weeks
Secondary Outcomes (7)
Cost-effectiveness: Incremental Cost
up to 30 weeks
Cost-effectiveness: Incremental Effectiveness
up to 30 weeks
Proportion of patients who engage with interventions
up to 18 weeks
Proportion of patients who reply opting out of receiving interventions
up to 30 weeks
Proportion of patients who complete SDM
up to 18 weeks
- +2 more secondary outcomes
Other Outcomes (1)
Baseline Characteristics that predict outcomes or moderate intervention effects
up to 30 weeks
Study Arms (6)
Stage 1: Repeated Text Messages (TM+)
OTHERParticipants will receive up to nine text messages containing eligibility questions, along with up to nine reminder messages. If a participant successfully responds to the eligibility questions, no more messages will be sent. If a participant does not respond to the eligibility questions after receiving a text message, they will receive a reminder message three days later, prompting them to answer the questions.
Stage 1: Repeated Text Messages and Chatbot (TM+/CA)
OTHERParticipants will receive up to nine text messages containing eligibility questions, along with up to nine reminder messages. If a participant successfully responds to the eligibility questions, no more messages will be sent. If a participant does not respond to the eligibility questions after receiving a text message, they will receive a reminder message three days later, prompting them to answer the questions. Participants will have access to a Lung Cancer Screening (LCS) Chatbot delivered via SMS.
Stage 1: Repeated Text Messages and Video (TM+/VID)
OTHERParticipants will receive up to nine text messages containing eligibility questions, along with up to nine reminder messages. If a participant successfully responds to the eligibility questions, no more messages will be sent. If a participant does not respond to the eligibility questions after receiving a text message, they will receive a reminder message three days later, prompting them to answer the questions. Participants can watch an educational video via SMS.
Stage 1: Repeated Text Messages, Chatbot, and Video (TM+/CA/VID)
OTHERParticipants will receive up to nine text messages containing eligibility questions, along with up to nine reminder messages. If a participant successfully responds to the eligibility questions, no more messages will be sent. If a participant does not respond to the eligibility questions after receiving a text message, they will receive a reminder message three days later, prompting them to answer the questions. Participants will have access to a Lung Cancer Screening (LCS) Chatbot delivered via SMS. Participants can watch an educational video via SMS.
Stage 2: Chatbot and Reactive Patient Navigation (CA/RPN)
OTHERRPN requires the participant to initiate the PN request. Participants receive up to three text messages scheduled four weeks apart.
Stage 2: Chatbot and Proactive Patient Navigation (CA/PPN)
OTHERPPN does not require the participant to initiate the PN request and instead is a proactive call to the participant. Participants receive up to three text messages scheduled four weeks apart.
Interventions
A message informs the participants that an RN from the Hub will call them about SDM and LCS.
Access to a chatbot for frequently asked questions about LCS
An educational video about LCS
RPN to help complete the LCS appointment. RPN requires the participant to initiate the PN request
Proactive patient navigation to help complete the LCS appointment. PPN does not require the participant to initiate the PN request and instead is a proactive call to the participant.
Eligibility Criteria
You may qualify if:
- Is currently a patient at participating CHCs
- Speak English or Spanish
- Current or former tobacco smoker
- Male or Female
- Age 50-80
- Electronic health records indicate they have not opted out of receiving text contact from the clinic
- Has a phone that can receive text messages
You may not qualify if:
- Persons with lung cancer or who have previously participated in a Shared Decision Making discussion with a health provider regarding lung cancer or have completed LCS.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Utahlead
- National Cancer Institute (NCI)collaborator
- Huntsman Cancer Institutecollaborator
Study Sites (1)
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
David Wetter, PhD, MS
Huntsman Cancer Institute/ University of Utah
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 13, 2026
First Posted
May 20, 2026
Study Start (Estimated)
August 1, 2026
Primary Completion (Estimated)
April 1, 2030
Study Completion (Estimated)
April 1, 2030
Last Updated
May 20, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share